Peer-driven intervention to prevent HIV, HCV, and drug overdoses among people who inject drugs

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot intervention focuses on reducing the transmission of HIV and hepatitis C virus, as well as overdose risk behaviors among people who inject drugs (PWID). Participants will be randomized into groups receiving peer education and access to risk reduction materials in semi-public injection settings, alongside standard care. The intervention is grounded in social influence and cognitive theories, aiming to enhance communication about risk behaviors and improve social norms. By increasing the availability of risk reduction materials and promoting peer outreach, the study seeks to reduce the sharing of injection equipment and improve naloxone access.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Current drug user (opioid use in the prior two weeks)

Exclusion Criteria:

* Any mental or physical health impairment that impedes ability to participate

Where it's running

• Lighthouse Studies at Peer Point
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Carl Latkin, PhD — Johns Hopkins Bloomberg School of Public Health
• Study coordinator: Carl Latkin, PhD
• Email: carl.latkin@jhu.edu
• Phone: 410-955-3972

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bile acid and gut microbiota changes in people with hepatitis D starting bulevirtide

  This project will see if starting bulevirtide changes bile acids and gut bacteria in adults with chronic hepatitis D who are already on hepatitis B therapy.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07429864

• Camino HIV Prevention and Care Study

  This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.

  Recruiting American University · Berkeley, California and 1 other locations · NCT07834853

• VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body

  This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.

  Recruiting at 2 sites Phase 1 ViiV Healthcare · Glendale, California and 1 other locations · NCT07818915

• Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use

  In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.

  Recruiting Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro · NCT07772791

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Screen2Prevent: HIV screening for teens and young adults in emergency departments

  The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.

  Recruiting at 5 sites Westat · Tampa, Florida and 4 other locations · NCT07728123

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.